Crispr Therapeutics AG (CRSP) — Capital Reinvestment Ratio
Latest as of March 2024:
0.01x
Crispr Therapeutics AG (CRSP) has a Capital Reinvestment Ratio of 0.01x as of March 2024, meaning it reinvests 0% of its operating cash flow ($109.75 Million) in capital expenditures ($721.00K). See CRSP cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
$109.75 Million
USD
Capital Expenditures
$721.00K
USD
Data as of
Mar 2024
Most recent filing
Crispr Therapeutics AG Capital Reinvestment Ratio (2015–2021)
This chart tracks Crispr Therapeutics AG's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Crispr Therapeutics AG (2015–2021)
Year-by-year Capital Reinvestment Ratio for Crispr Therapeutics AG from 2015 to 2021. For live market cap and broader valuation context, see Crispr Therapeutics AG stock valuation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.15x | $538.97 Million | $81.70 Million | ▲ +28.5% |
| 2019 | 0.12x | $56.68 Million | $6.68 Million | ▲ +507.3% |
| 2015 | 0.02x | $59.43 Million | $1.15 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow